Perspective
Aug. 28, 2013
Myriad threatens patentability of in vitro stem cells
We are only starting to see the effects of the high court's gene-patentability decision; one concrete example can be seen in a challenge brought related to cultures of human embryonic stem cells. By Jason G. Harp and George Yu
We are only starting to see the effects of the Supreme Court's recent decision finding that isolated, naturally occurring sequences of DNA are not patentable subject matter because they are products of nature, long held to be unpatentable under 35 U.S.C. 101. Association for Molecular Pathology v. Myriad Genetics Inc., 2013 DJDAR 7484 (2013). One concrete consequence can be seen in the challenge brought against Wisconsin ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In